Logo

CMPS

COMPASS Pathways plc

CMPS

COMPASS Pathways plc • NASDAQ
$5.55 ▲ 6.12% (+0.32)
Market Cap $532.81 M
52w High $7.08
52w Low $2.25
Dividend Yield 0%
P/E -2.04
Volume 405.46K
Outstanding Shares 96.00M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $40.536M ▼ $-137.717M ▼ 0% $-1.44 ▼ $-136.834M ▼
Q2-2025 $0 $42.933M ▼ $-38.403M ▼ 0% $-0.41 ▼ $-36.957M ▼
Q1-2025 $0 $49.616M ▲ $-17.864M ▲ 0% $-0.2 ▲ $-16.349M ▲
Q4-2024 $0 $48.414M ▲ $-43.332M ▼ 0% $-0.63 ▼ $-41.127M ▼
Q3-2024 $0 $47.896M $-38.502M 0% $-0.56 $-37.133M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $185.937M ▼ $255.607M ▼ $218.016M ▲ $37.591M ▼
Q2-2025 $221.881M ▼ $293.536M ▼ $130.981M ▲ $162.555M ▼
Q1-2025 $260.11M ▲ $319.135M ▲ $123.668M ▲ $195.467M ▲
Q4-2024 $165.081M ▼ $213.666M ▼ $58.971M ▲ $154.695M ▼
Q3-2024 $206.953M $247.338M $54.308M $193.03M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-137.717M ▼ $-35.106M ▲ $0 $0 ▼ $-35.944M ▲ $-35.106M ▲
Q2-2025 $-38.403M ▼ $-38.689M ▲ $0 $166K ▼ $-38.229M ▼ $-38.689M ▲
Q1-2025 $-17.864M ▲ $-45.657M ▼ $0 $140.359M ▲ $95.019M ▲ $-45.657M ▼
Q4-2024 $-43.332M ▼ $-41.757M ▼ $0 $155K ▲ $-41.872M ▼ $-41.757M ▼
Q3-2024 $-38.502M $-22.185M $0 $-53K $-21.675M $-22.185M

Five-Year Company Overview

Income Statement

Income Statement COMPASS Pathways is a classic clinical‑stage story: it has no product revenue yet and its entire income statement is driven by research and corporate spending. Losses have steadily grown as trials have scaled up, then leveled off somewhat in the most recent years. This pattern is typical for a company moving from early to late‑stage clinical development. The key point is that the business is still firmly in the investment phase, with ongoing, meaningful operating and net losses and no commercial offset from sales yet. Future results will depend heavily on clinical trial outcomes and eventual regulatory decisions, rather than past financial performance.

Balance Sheet

Balance Sheet The balance sheet is dominated by cash and similar assets, which is what you would expect for a pre‑revenue biotech funding multi‑year trials. Cash levels rose after going public and then have trended down as funds are used to support operations. Equity has been shrinking as accumulated losses build up, and a modest amount of debt has appeared in the last couple of years, where previously there was none. Overall, the company still looks capital‑light in terms of physical assets, but increasingly reliant on external capital to replenish its cash as development continues.

Cash Flow

Cash Flow Cash flow clearly reflects a cash‑burn story. Operating cash flows have been consistently negative over the past several years, and free cash flow closely tracks this since there is essentially no heavy spending on equipment or facilities. Most cash out the door is tied to R&D, clinical trials, and overhead, not long‑term physical assets. This means the company’s runway is mainly a question of how quickly it spends on development versus how easily it can raise new capital. Until there is a commercial product, investors and management must expect continued negative cash flow.

Competitive Edge

Competitive Edge COMPASS occupies a leading niche in psychedelic‑assisted mental health therapy, especially for treatment‑resistant depression. Its main advantages are being early in the race with an advanced late‑stage program, holding specialized patents around its psilocybin formulation, and having an FDA “Breakthrough Therapy” designation that can smooth regulatory interactions. It is also differentiating itself by pairing the drug with a structured therapy model and digital tools. Against this, the company operates in a very uncertain and crowded landscape: regulators are cautious, social and political views on psychedelics are evolving, and there are both traditional antidepressant competitors and new psychedelic entrants chasing similar opportunities. Pricing, insurance coverage, and clinic adoption are all open questions that could significantly influence its eventual competitive strength.

Innovation and R&D

Innovation and R&D Innovation is the core of the COMPASS story. The company’s lead asset, COMP360, is a proprietary synthetic form of psilocybin being tested in large, late‑stage trials for people who have not responded to standard depression treatments. Beyond the drug itself, COMPASS is building a broader platform: therapist training tools, patient apps, and data‑driven, AI‑based systems to better predict and personalize outcomes. It is also testing COMP360 in additional conditions like PTSD and anorexia, and is involved in work on next‑generation psychedelic compounds. This shows a strategy aimed at building a long‑term pipeline and an integrated care model, rather than relying on a single product alone.

Summary

Overall, COMPASS Pathways is a high‑risk, high‑uncertainty, innovation‑driven company. Financially, it is pre‑revenue, loss‑making, and cash‑consuming, which is typical for a clinical‑stage biotech but means ongoing dependence on external funding. Strategically, it holds a strong early position in a very new category of mental health treatment, backed by advanced clinical trials, regulatory recognition, and a thoughtful therapy plus digital ecosystem. The key variables going forward are clinical outcomes, regulatory decisions, public and payer acceptance of psychedelic therapies, and the company’s ability to manage its cash burn and capital needs as it moves toward potential commercialization.

NEWS

November 20, 2025 · 6:30 AM UTC

Compass Pathways to Participate in Two Investor Conferences in December

Read more

November 5, 2025 · 6:30 AM UTC

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Read more

November 4, 2025 · 6:30 AM UTC

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Read more

October 30, 2025 · 8:30 AM UTC

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

Read more

October 29, 2025 · 6:30 AM UTC

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

Read more